Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016311 | Colorectum | AD | dephosphorylation | 123/3918 | 417/18723 | 1.84e-05 | 3.82e-04 | 123 |
GO:0006470 | Colorectum | AD | protein dephosphorylation | 88/3918 | 281/18723 | 2.56e-05 | 4.89e-04 | 88 |
GO:00064701 | Colorectum | SER | protein dephosphorylation | 65/2897 | 281/18723 | 4.44e-04 | 6.51e-03 | 65 |
GO:0051051 | Colorectum | SER | negative regulation of transport | 98/2897 | 470/18723 | 1.01e-03 | 1.19e-02 | 98 |
GO:00163111 | Colorectum | SER | dephosphorylation | 86/2897 | 417/18723 | 2.73e-03 | 2.46e-02 | 86 |
GO:0032409 | Colorectum | SER | regulation of transporter activity | 65/2897 | 310/18723 | 5.71e-03 | 4.19e-02 | 65 |
GO:00064702 | Colorectum | MSS | protein dephosphorylation | 73/3467 | 281/18723 | 1.15e-03 | 1.12e-02 | 73 |
GO:00163112 | Colorectum | MSS | dephosphorylation | 101/3467 | 417/18723 | 1.98e-03 | 1.70e-02 | 101 |
GO:00324091 | Colorectum | MSS | regulation of transporter activity | 78/3467 | 310/18723 | 2.09e-03 | 1.78e-02 | 78 |
GO:00510511 | Colorectum | MSS | negative regulation of transport | 110/3467 | 470/18723 | 4.20e-03 | 3.04e-02 | 110 |
GO:00163113 | Colorectum | FAP | dephosphorylation | 95/2622 | 417/18723 | 7.07e-07 | 3.32e-05 | 95 |
GO:00064704 | Colorectum | FAP | protein dephosphorylation | 69/2622 | 281/18723 | 1.47e-06 | 6.39e-05 | 69 |
GO:00324092 | Colorectum | FAP | regulation of transporter activity | 67/2622 | 310/18723 | 1.59e-04 | 2.43e-03 | 67 |
GO:00510512 | Colorectum | FAP | negative regulation of transport | 91/2622 | 470/18723 | 7.09e-04 | 7.64e-03 | 91 |
GO:00163114 | Colorectum | CRC | dephosphorylation | 79/2078 | 417/18723 | 1.27e-06 | 7.21e-05 | 79 |
GO:00064705 | Colorectum | CRC | protein dephosphorylation | 57/2078 | 281/18723 | 4.49e-06 | 1.87e-04 | 57 |
GO:00324093 | Colorectum | CRC | regulation of transporter activity | 59/2078 | 310/18723 | 2.34e-05 | 6.65e-04 | 59 |
GO:00510513 | Colorectum | CRC | negative regulation of transport | 71/2078 | 470/18723 | 4.33e-03 | 3.47e-02 | 71 |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CTTNBP2NL | SNV | Missense_Mutation | novel | c.636C>A | p.Ser212Arg | p.S212R | Q9P2B4 | protein_coding | tolerated(0.19) | benign(0.188) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CTTNBP2NL | SNV | Missense_Mutation | | c.1364N>A | p.Ile455Asn | p.I455N | Q9P2B4 | protein_coding | deleterious(0) | possibly_damaging(0.691) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTTNBP2NL | SNV | Missense_Mutation | | c.1807N>T | p.His603Tyr | p.H603Y | Q9P2B4 | protein_coding | tolerated(0.27) | benign(0.099) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CTTNBP2NL | SNV | Missense_Mutation | | c.1894G>C | p.Glu632Gln | p.E632Q | Q9P2B4 | protein_coding | deleterious(0.02) | benign(0.287) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
CTTNBP2NL | SNV | Missense_Mutation | novel | c.1768N>C | p.Thr590Pro | p.T590P | Q9P2B4 | protein_coding | deleterious(0) | benign(0.091) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
CTTNBP2NL | SNV | Missense_Mutation | rs754747435 | c.775N>T | p.Arg259Trp | p.R259W | Q9P2B4 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-E2-A1IE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
CTTNBP2NL | SNV | Missense_Mutation | | c.1723N>C | p.Glu575Gln | p.E575Q | Q9P2B4 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-GM-A2DH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
CTTNBP2NL | insertion | Nonsense_Mutation | novel | c.1053_1054insATTACATGGTCATTGTGCTTACAATGAAAAACAGTTTTC | p.His351_Cys352insIleThrTrpSerLeuCysLeuGlnTerLysThrValPhe | p.H351_C352insITWSLCLQ*KTVF | Q9P2B4 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CTTNBP2NL | insertion | Nonsense_Mutation | novel | c.1681_1682insTCGCTTGAACCCAGAAGGCGGAGGTTGCAGTGAG | p.Pro561LeufsTer3 | p.P561Lfs*3 | Q9P2B4 | protein_coding | | | TCGA-BH-A0B8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
CTTNBP2NL | insertion | Nonsense_Mutation | novel | c.1322_1323insCACCTCTTATCTAACTATATAAAAATGTATATTATT | p.Ser441_Ala442insThrSerTyrLeuThrIleTerLysCysIleLeuLeu | p.S441_A442insTSYLTI*KCILL | Q9P2B4 | protein_coding | | | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |